Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant

Allogeneic hematopoietic cell transplantation (alloHCT) is a potentially curative treatment for myelodysplastic syndromes (MDS), but patients who relapse after transplant have poor outcomes. In order to understand the contribution of tumor clonal evolution to disease progression,we applied exome and...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:JCI Insight
Autori principali: Jacoby, Meagan A., Duncavage, Eric J., Chang, Gue Su, Miller, Christopher A., Shao, Jin, Elliott, Kevin, Robinson, Joshua, Fulton, Robert S., Fronick, Catrina C., O’Laughlin, Michelle, Heath, Sharon E., Pusic, Iskra, Welch, John S., Link, Daniel C., DiPersio, John F., Westervelt, Peter, Ley, Timothy J., Graubert, Timothy A., Walter, Matthew J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society for Clinical Investigation 2018
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5922277/
https://ncbi.nlm.nih.gov/pubmed/29515031
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.98962
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi